Foghorn Therapeutics
Saurabh Sewak, PhD, currently serves as the Head of Business Development and VP of Corporate Development at Foghorn Therapeutics Inc., leading efforts in clinical and preclinical oncology asset development. Additionally, Saurabh is the Vice Chair of the Board of Trustees for the Leukemia & Lymphoma Society in New England, focusing on enhancing representation for underrepresented patient groups. As the founder of Sewaa Strategies Biopharma Advisory, Saurabh provides strategic guidance to biotech companies in areas such as corporate strategy and clinical development. Previous roles include leadership positions at Ipsen, TESARO, and Biogen, where Saurabh drove corporate strategy, commercial development, and business partnerships. Educational background includes a PhD and an MS in Pharmacy from the University of Mississippi, along with a Bachelor of Pharmacy from Savitribai Phule Pune University.
Foghorn Therapeutics
1 followers
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Their proprietary Gene Traffic Control platform gives them an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing them to identify, validate, and potential drug targets within the system.